Torrent Pharma’s Gujarat facility gets one USFDA observation

Torrent Pharma’s Gujarat facility gets one USFDA observation

[ad_1]



Torrent Pharmaceuticals said the US Food and Drug Administration (USFDA) has conducted a pre-approval inspection (PAI) at its oral oncology manufacturing facility in Bileshwarpura, Gujarat.

The inspection took place from March 13-17, 2023. Following the inspection, the USFDA issued a Form 483 with a remark.

We will respond to the USFDA within the stipulated time frame and will work closely with the USFDA to address the observation as soon as possible, the company said in the exchange filing.

Torrent Pharmaceuticals is the flagship company of the Torrent Group. It ranks 7th in the Indian Pharmaceuticals Market and ranks in the top 5 in the therapeutic segments of Cardiovascular (CV), Gastrointestinal (GI), Central Nervous System (CNS) and Nutritional Vitamin Minerals (VMN).

On a consolidated basis, the company’s net profit increased by 13.7% to Rs 283 crore with an 18.17% increase in net income from operations to Rs 2491 crore in the third quarter of the fiscal year. 23 with respect to the third quarter of fiscal year 22.

The voucher was down 0.21% at Rs 1,527.35 on the BSE.

powered by Capital Markets – Live News

(This story has not been edited by Business Standard staff and is automatically generated from a syndicated feed.)

Subscribe to Business Standard Premium

Exclusive stories, curated newsletters, 26 years of archives, e-paper and more!


[ad_2]

Leave a Comment

Comments

No comments yet. Why don’t you start the discussion?

Leave a Reply

Your email address will not be published. Required fields are marked *